Stay updated on COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma
Sign up to get notified when there's something new on the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page.

Latest updates to the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page
- Check5 days agoChange DetectedRevision history updated: added Revision v3.3.4 and removed Revision v3.3.3.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedA new Revision: v3.3.3 was added, and the HHS Vulnerability Disclosure link as well as the previous Revision: v3.3.2 entry were removed.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page history shows a minor revision update (v3.3.2) replacing v3.3.1, a footer-level change with no impact on core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check55 days agoChange DetectedThe history shows an addition of Revision: v3.3.1 and a deletion of Revision: v3.2.0, indicating a routine site update with no impact on trial data or page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedThe top banner informing users about government funding and potential delays was removed. The page now shows the record history without that informational notice.SummaryDifference0.2%

- Check77 days agoChange DetectedThe page history introduces a Recruitment Status entry in the navigation, and subsequent versions show updates to Study Status and related sections.SummaryDifference0.1%

Stay in the know with updates to COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma
Enter your email address, and we'll notify you when there's something new on the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page.